Steve Soper,
Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine,
The University of Kansas
Prof. Soper is currently a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas, Lawrence. Prof. Soper also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. He is also serving as a Science Advisor for a number of major worldwide companies. Prof. Soper is currently on the Editorial Board for Scientific Reports and Journal of Micro- and Nanosystems.
As a result of his efforts, Prof. Soper has secured extramural funding totaling >$103M and has published over 265 peer-reviewed manuscripts (h index = 71) and is the author of 20 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 60 PhDs and 6 MS degrees to students under his mentorship. He currently heads a group of 20 researchers.
Integrated Microfluidic System for Single Cell Analysis of Circulating Tumor Cell Sub-populations with Divergent Phenotypes
Thursday, 18 September 2014 at 10:15
Add to Calendar ▼2014-09-18 10:15:002014-09-18 11:15:00Europe/LondonIntegrated Microfluidic System for Single Cell Analysis of Circulating Tumor Cell Sub-populations with Divergent PhenotypesExosomes and Single Cell Analysis Summit in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
While metastatic disease causes ~90% of all cancer related deaths,
determining the role of various cancer cells, either from the primary
tumor or those in circulation (circulating tumor cells, CTCs), in the
metastatic process has been difficult due to the continuum of phenotypes
they possess and/or the rare nature of these cells, especially CTCs. To
assist in studies based on the use of rare CTCs that may be involved in
metastasis, an integrated microfluidic system was designed, fabricated
and evaluated, which could select multiple types of cells, including
cells that have an epithelial phenotype and those that possess the
ability to digest the extracellular matrix (ECM).
Add to Calendar ▼2014-09-18 00:00:002014-09-19 00:00:00Europe/LondonExosomes and Single Cell Analysis SummitExosomes and Single Cell Analysis Summit in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com